Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Prime Medicine, Inc. ( (PRME) ).
On April 7, 2026, Prime Medicine’s board appointed Svetlana Makhni, a veteran biotechnology and healthcare finance executive with more than two decades of investment banking and CFO experience, as Chief Financial Officer and principal financial officer effective April 16, 2026. Her employment package includes a $495,000 base salary, performance-based bonus eligibility, tiered severance and change-of-control protections, and stock options for up to 900,000 shares tied to time-based and milestone vesting, while existing CEO Allan Reine will relinquish the principal financial officer title but remain chief executive and principal executive officer, signaling a clearer separation of financial and operational leadership roles.
The most recent analyst rating on (PRME) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Prime Medicine, Inc. stock, see the PRME Stock Forecast page.
Spark’s Take on PRME Stock
According to Spark, TipRanks’ AI Analyst, PRME is a Neutral.
Score is held back primarily by weak financial performance (large ongoing losses, significant cash burn, and increased debt), partially offset by improving technical momentum and constructive corporate updates on pipeline progress and runway. Valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on PRME stock, click here.
More about Prime Medicine, Inc.
Prime Medicine, Inc. operates in the biotechnology sector, focusing on developing advanced therapies and leveraging capital markets expertise to support growth. The company’s leadership structure integrates seasoned financial and operational executives with backgrounds in clinical-stage biotech and healthcare services, reflecting a focus on disciplined financing and strategic transactions.
Average Trading Volume: 2,664,887
Technical Sentiment Signal: Buy
Current Market Cap: $684.3M
For an in-depth examination of PRME stock, go to TipRanks’ Overview page.